Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial (Q43739514)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial |
scientific article |
Statements
1 reference
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial (English)
1 reference
M J Ellis
1 reference
A Coop
1 reference
B Singh
1 reference
L Mauriac
1 reference
A Llombert-Cussac
1 reference
F Jänicke
1 reference
W R Miller
1 reference
D B Evans
1 reference
M Dugan
1 reference
C Brady
1 reference
E Quebe-Fehling
1 reference
M Borgs
1 reference
1 September 2001
1 reference
1 reference
Identifiers
1 reference